Literature DB >> 27922620

Relevance of necroptosis in cancer.

Najoua Lalaoui1,2, Gabriela Brumatti1,2.   

Abstract

Resistance to caspase-dependent apoptosis is often responsible for treatment failures in cancer. Finding novel therapeutic strategies that can activate alternative cell death programs appears to be appealing. Necroptosis is a form of programmed necrosis that occurs under caspase-deficient conditions. This alternative form of cell death has recently emerged as a potential anticancer therapy that could overcome apoptosis resistance. A growing understanding of the molecular events triggering necroptosis helped to examine its implication in cancer development and to define new therapeutic strategies. Genetic and proteomic analysis suggest that necroptosis is deregulated in many cancers. Various preclinical and clinical compounds induced necroptosis and have demonstrated significant therapeutic efficacy. Moreover, accumulating evidence has shown that necroptosis promotes anticancer immune response. A better knowledge of the cascade of events regulating necroptosis is expected to assess the feasibility of its therapeutic exploitation for cancer therapy.

Entities:  

Mesh:

Year:  2016        PMID: 27922620     DOI: 10.1038/icb.2016.120

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  98 in total

1.  RIPK1 maintains epithelial homeostasis by inhibiting apoptosis and necroptosis.

Authors:  Marius Dannappel; Katerina Vlantis; Snehlata Kumari; Apostolos Polykratis; Chun Kim; Laurens Wachsmuth; Christina Eftychi; Juan Lin; Teresa Corona; Nicole Hermance; Matija Zelic; Petra Kirsch; Marijana Basic; Andre Bleich; Michelle Kelliher; Manolis Pasparakis
Journal:  Nature       Date:  2014-08-17       Impact factor: 49.962

2.  IAPs limit activation of RIP kinases by TNF receptor 1 during development.

Authors:  Maryline Moulin; Holly Anderton; Anne K Voss; Tim Thomas; Wendy Wei-Lynn Wong; Aleksandra Bankovacki; Rebecca Feltham; Diep Chau; Wendy D Cook; John Silke; David L Vaux
Journal:  EMBO J       Date:  2012-02-10       Impact factor: 11.598

3.  Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.

Authors:  Sean L Petersen; Lai Wang; Asligul Yalcin-Chin; Lin Li; Michael Peyton; John Minna; Patrick Harran; Xiaodong Wang
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

4.  RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3.

Authors:  Christopher P Dillon; Ricardo Weinlich; Diego A Rodriguez; James G Cripps; Giovanni Quarato; Prajwal Gurung; Katherine C Verbist; Taylor L Brewer; Fabien Llambi; Yi-Nan Gong; Laura J Janke; Michelle A Kelliher; Thirumala-Devi Kanneganti; Douglas R Green
Journal:  Cell       Date:  2014-05-08       Impact factor: 41.582

5.  The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.

Authors:  Gabriela Brumatti; Chunyan Ma; Najoua Lalaoui; Nhu-Y Nguyen; Mario Navarro; Maria C Tanzer; Jennifer Richmond; Margherita Ghisi; Jessica M Salmon; Natasha Silke; Giovanna Pomilio; Stefan P Glaser; Elisha de Valle; Raffi Gugasyan; Mark A Gurthridge; Stephen M Condon; Ricky W Johnstone; Richard Lock; Guy Salvesen; Andrew Wei; David L Vaux; Paul G Ekert; John Silke
Journal:  Sci Transl Med       Date:  2016-05-18       Impact factor: 17.956

6.  Widespread mitochondrial depletion via mitophagy does not compromise necroptosis.

Authors:  Stephen W G Tait; Andrew Oberst; Giovanni Quarato; Sandra Milasta; Martina Haller; Ruoning Wang; Maria Karvela; Gabriel Ichim; Nader Yatim; Matthew L Albert; Grahame Kidd; Randall Wakefield; Sharon Frase; Stefan Krautwald; Andreas Linkermann; Douglas R Green
Journal:  Cell Rep       Date:  2013-11-21       Impact factor: 9.423

7.  RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition.

Authors:  William J Kaiser; Lisa P Daley-Bauer; Roshan J Thapa; Pratyusha Mandal; Scott B Berger; Chunzi Huang; Aarthi Sundararajan; Hongyan Guo; Linda Roback; Samuel H Speck; John Bertin; Peter J Gough; Siddharth Balachandran; Edward S Mocarski
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

8.  RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species.

Authors:  Qiong Wang; Wenshu Chen; Xiuling Xu; Bilan Li; Weiyang He; Mabel T Padilla; Jun-Ho Jang; Toru Nyunoya; Shantu Amin; Xia Wang; Yong Lin
Journal:  Carcinogenesis       Date:  2013-04-30       Impact factor: 4.944

9.  The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma.

Authors:  Seongmi Park; Kimmo J Hatanpaa; Yang Xie; Bruce E Mickey; Christopher J Madden; Jack M Raisanen; Deepti B Ramnarain; Guanghua Xiao; Debabrata Saha; David A Boothman; Dawen Zhao; Robert M Bachoo; Russell O Pieper; Amyn A Habib
Journal:  Cancer Res       Date:  2009-04-01       Impact factor: 12.701

10.  Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation.

Authors:  Young Sik Cho; Sreerupa Challa; David Moquin; Ryan Genga; Tathagat Dutta Ray; Melissa Guildford; Francis Ka-Ming Chan
Journal:  Cell       Date:  2009-06-12       Impact factor: 41.582

View more
  16 in total

1.  Necroptotic death signaling: evolution, mechanisms and disease relevance.

Authors:  James E Vince
Journal:  Immunol Cell Biol       Date:  2017-02       Impact factor: 5.126

2.  Necroptosis of tumor cells leads to tumor necrosis and promotes tumor metastasis.

Authors:  Delong Jiao; Zhenyu Cai; Swati Choksi; Dan Ma; Moran Choe; Hyung-Joon Kwon; Jin Young Baik; Brian G Rowan; Chengyu Liu; Zheng-Gang Liu
Journal:  Cell Res       Date:  2018-06-25       Impact factor: 25.617

Review 3.  MLKL in cancer: more than a necroptosis regulator.

Authors:  Peter Vandenabeele; Nozomi Takahashi; Sofie Martens; Jolien Bridelance; Ria Roelandt
Journal:  Cell Death Differ       Date:  2021-05-05       Impact factor: 12.067

4.  Sestrin 2 suppresses cells proliferation through AMPK/mTORC1 pathway activation in colorectal cancer.

Authors:  Jin-Lai Wei; Min Fang; Zhong-Xue Fu; Shou-Ru Zhang; Jin-Bao Guo; Rong Wang; Zhen-Bing Lv; Yong-Fu Xiong
Journal:  Oncotarget       Date:  2017-07-25

5.  Evaluation of cell death pathways initiated by antitumor drugs melatonin and valproic acid in bladder cancer cells.

Authors:  Siwei Liu; Bilin Liang; Huiting Jia; Yuhan Jiao; Zhongqiu Pang; Yongye Huang
Journal:  FEBS Open Bio       Date:  2017-04-27       Impact factor: 2.693

Review 6.  Medicinal Plants from Brazilian Cerrado: Antioxidant and Anticancer Potential and Protection against Chemotherapy Toxicity.

Authors:  José Tarcísio de Giffoni de Carvalho; Débora da Silva Baldivia; Daniel Ferreira Leite; Laura Costa Alves de Araújo; Priscilla Pereira de Toledo Espindola; Katia Avila Antunes; Paola Santos Rocha; Kely de Picoli Souza; Edson Lucas Dos Santos
Journal:  Oxid Med Cell Longev       Date:  2019-08-25       Impact factor: 6.543

7.  Activation of Necroptosis by Engineered Self Tumor-Derived Exosomes Loaded with CRISPR/Cas9.

Authors:  Diana Gulei; Ioana Berindan-Neagoe
Journal:  Mol Ther Nucleic Acids       Date:  2019-07-03

Review 8.  Necroptosis in Cholangiocarcinoma.

Authors:  Samantha Sarcognato; Iris E M de Jong; Luca Fabris; Massimiliano Cadamuro; Maria Guido
Journal:  Cells       Date:  2020-04-15       Impact factor: 6.600

9.  One-Pot Radiosynthesis and Biological Evaluation of a Caspase-3 Selective 5-[123,125I]iodo-1,2,3-triazole derived Isatin SPECT Tracer.

Authors:  Matthias Glaser; Vineeth Rajkumar; Seckou Diocou; Thibault Gendron; Ran Yan; Pak Kwan Brian Sin; Kerstin Sander; Laurence Carroll; R Barbara Pedley; Eric O Aboagye; Timothy H Witney; Erik Årstad
Journal:  Sci Rep       Date:  2019-12-17       Impact factor: 4.379

Review 10.  Necroptosis in Immuno-Oncology and Cancer Immunotherapy.

Authors:  Jenny Sprooten; Pieter De Wijngaert; Isaure Vanmeerbeerk; Shaun Martin; Peter Vangheluwe; Susan Schlenner; Dmitri V Krysko; Jan B Parys; Geert Bultynck; Peter Vandenabeele; Abhishek D Garg
Journal:  Cells       Date:  2020-08-01       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.